Visible Light‐Induced Decarboxylative Alkylation of Heterocyclic Aromatics with Carboxylic Acids via Anthocyanin as a Photocatalyst
作者:Rui Guo、Minghui Zuo、Qinye Tian、Chuanfu Hou、Shouneng Sun、Weihao Guo、Hongfeng Wu、Wenyi Chu、Zhizhong Sun
DOI:10.1002/asia.202000277
日期:2020.7
A visiblelight‐induced decarboxylative alkylation of heterocyclic aromatics with aliphatic carboxylicacids was developed by using anthocyanins as a photocatalyst under mild conditions. A series of alkylated heterocyclic compounds were obtained in moderate to good yields by using the metal‐free decarboxylative coupling reaction under blue light. This strategy uses cheap and readily available carboxylic
A novel and efficient silver catalyzed decarboxylative direct C2-alkylation of benzothiazoles with carboxylic acids for the synthesis of 2-alkyl benzothiazoles was developed.
Molecular probes for ascorbate detection and methods of use
申请人:The University of Hong Kong
公开号:US10018623B1
公开(公告)日:2018-07-10
Described are metal complexes for the selective detection of ascorbic acid or ascorbate. The metal complexes act as molecular sensors, and are useful in detecting ascorbate in live biological samples, commercial samples, or both. The selective ascorbate sensing involves an ascorbate-selective bond cleavage reaction. The bond cleavage is not limited to the construction of molecular sensors, but also includes other stimuli-responsive materials, i.e., materials that adopt a physical state, such as gel formation, upon ascorbate-selective bond cleavage of the metal complexes.
alpha-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD
申请人:NATIONAL INSTITUTES FOR QUANTUM AND
RADIOLOGICAL SCIENCE AND TECHNOLOGY
公开号:EP3932405A1
公开(公告)日:2022-01-05
The present invention provides an α-synuclein aggregate binding agent that has high binding selectivity for an α-synuclein aggregate.
The α-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof:
in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii):
R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.
本发明提供了一种α-突触核蛋白聚集体结合剂,它对α-突触核蛋白聚集体具有高结合选择性。
α-突触核蛋白聚集体结合剂含有由式(I)代表的化合物、其药学上可接受的盐或其溶液:
在式 (I) 中,R1 和 R2 各自独立地选自氢、烷基、烯基、酰基和羟烷基组成的组;R3 是氢或卤素;环 A 是苯环或吡啶环;环 B 由下式 (i) 或 (ii) 表示:
R4 和 R5 各自独立地选自氢、羟基、烷氧基、卤代烷氧基、卤代羟基烷氧基和氨基烷基组成的组。
Therapy for inhibition of single-stranded RNA virus replication
申请人:RedHill Biopharma Ltd.
公开号:US10543222B2
公开(公告)日:2020-01-28
Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.